Melatonin and Polyphenols - A comparative study of the nutritional and bioactive compounds content of walnut (Juglans regia) was conducted by María Isabel Tapia from Instituto Tecnológico Agroalimentario de Extremadura, Spain. In her journal she mentioned the presence of Proteins and fats which accounted for more than 70% of the walnut. The content in bioactive compounds were melatonin, serotonin, and total phenols, high content of magnesium and other minerals, and polyunsaturated fatty which were accounted for as their healthful properties, potentially beneficial to health.

Melatonin: A study conducted by Antía Verde from Universidade de Vigo, Departamento de Biología Funcional, Spain. This study investigated the presence of melatonin in nuts using chromatographic techniques and optimized extraction procedures according to the high oil content of nuts. Melatonin was detected in walnuts. The study shows the melatonin content in walnut seeds decreased sharply during the ripening process from the ripe green stage to the mature dehydrated fruit and increased after harvesting when the fruits were edible. Therefore, this study reveals new data on the presence of melatonin in walnut seeds in a natural format. 

• Reduction in Cortisol: In an open-label clinical trial involving 45 subjects diagnosed with Generalized Anxiety Disorder (GAD), salivary cortisol levels were assessed over three days before and after treatment at specific intervals throughout the day. Mixed model analyses revealed a significant association between symptomatic improvement during treatment and changes in cortisol levels. Subjects experiencing greater symptomatic improvement showed significant increases in morning salivary cortisol and a greater decrease in cortisol levels throughout the day. Previous research indicated elevated methylation of the NR3C1 promoter gene in GAD patients, correlating with diminished glucocorticoid receptor transcription, suggesting desensitization of the cortisol system in GAD. Minimal research has explored cortisol indicators in GAD treatment, particularly in adults. In this study, salivary cortisol was measured to investigate its association with symptomatic improvement in GAD treatment using chamomile extract. It was hypothesized that increases in morning cortisol and changes in diurnal cortisol slope post-treatment would correlate with superior symptomatic change, controlling for baseline symptom severity and cortisol levels. Additionally, baseline cortisol levels were explored as predictors of treatment response.
• Generalized Anxiety Disorder: In a study, 180 subjects with moderate to severe Generalized Anxiety Disorder (GAD) will receive pharmaceutical-grade chamomile extract in an initial open-label phase for 8 weeks, with doses ranging from 500 to 1,500 mg daily. Responders to the treatment will undergo an additional 4 weeks of consolidation therapy. Subsequently, they will be randomized to double-blind continuation therapy with either chamomile extract or placebo for 26 weeks. The primary outcome measure will be the time to relapse during continuation therapy, with secondary outcomes including the proportion of subjects experiencing relapse and the incidence of treatment-emergent adverse events. Quality of life ratings will also be assessed during short and long-term therapy. This study aims to evaluate the safety and efficacy of chamomile extract in the long-term treatment of GAD, building upon prior findings demonstrating its superiority over placebo in reducing GAD symptoms.
• Anxiety disorder: In a study, 180 subjects with moderate to severe Generalized Anxiety Disorder (GAD) will receive chamomile extract for 8 weeks. Responders will undergo an additional 4 weeks of consolidation therapy and then be randomized to either chamomile extract or placebo for 26 weeks of double-blind continuation therapy. The primary outcome is time to relapse during continuation therapy. Secondary outcomes include the proportion of subjects experiencing relapse, treatment-emergent adverse events, and quality of life ratings. This study aims to evaluate the long-term safety and efficacy of chamomile extract for GAD, building on previous findings of its effectiveness compared to placebo.
• Depression: A three-armed, parallel, randomized, controlled trial involved 183 participants divided into lavender, chamomile, and control groups (n=61 each). The experimental groups inhaled three drops of 1.5% lavender or chamomile essential oils for 30 nights, while the control group inhaled distilled water. Depression, anxiety, and stress levels were measured using the Depression, Anxiety, and Stress Scale (DASS) at baseline, immediately after the intervention, and one month later. Statistically significant improvements in depression, anxiety, and stress were observed in the lavender and chamomile groups compared to the control group both immediately and one month after the intervention (p<0.01). The study concluded that inhalation aromatherapy with lavender and chamomile essential oils effectively reduced depression, anxiety, and stress levels in community-dwelling older adults.
  
  

Managing Insomnia: A pilot clinical trial was conducted by Prathibha C. K., Anandaraman P.V and Gopal G Nanda the Incharge of Dr. A. L. Research Centre for Ayurveda in Tamil Nadu on 10 individuals who were suffering from insomnia. They were administered with Myristica fragrans powder daily after food for 14 days. After 14 days of regular administration of jaiphal, it was concluded that jaiphal is an effective drug in managing insomnia.

Antibacterial: A research was conducted by Ben Lagha, O.M from the Department of Food Science, University Putra Malaysia to understand the antibacterial activity of Nutmeg extract on against foodborne pathogens. The nutmeg extract along with crude oil and distilled water was used on food under various conditions and temperatures. After the 10th and 14th day of examination, it was concluded that Nutmeg (M. fragrans Houtt.) extract exhibited antibacterial activity against foodborne pathogens and can be used as a natural preservative. 

Antioxidant and antibacterial: A review on Antioxidant and Antimicrobial Activity of Nutmeg was conducted and published in Academic Press by Ashish Deep Gupta from Mangalayatan University, Uttar Pradesh. He cited in the journal that various extracts and the essential oil of nutmeg seeds have presented strong antimicrobial activity and due to its high antioxidant and antimicrobial activities, nutmeg could be considered as a significant natural source of antioxidants and antimicrobials. Nutmeg, being a natural product, can offer more safety to people and the environment and is considered to be less of a risk for resistance development by pathogenic microorganisms.

Immunity Report: A review was conducted by Rafia Rehman from the University of Okara, Pakistan on the uses and biological properties of Nutmeg. She cited that Nutmeg is considered an essential ingredient in numerous industrial applications ranging from food to cosmetics. Its pharmaceutical products are also important due to its antioxidant and antimicrobial properties. Her finding on the Immuno-modulatory and radio-protective activities of nutmeg was similar. The lignans present in fresh nutmeg show radio modifying and immune-modulatory properties, present in the aqueous extract of fresh nutmeg.

Generalized Anxiety Disorder:

• The study aimed to assess the efficacy of a 70% hydro-ethanolic extract of Centella asiatica (CA) in treating generalized anxiety disorder (GAD) in humans. Thirty-three participants, comprising 18 males and 15 females with an average age of 33 years, were administered CA capsules twice daily (500 mg/capsule) after meals for 60 days. The subjects were evaluated at baseline (day 0), mid-term (day 30), and final (day 60) using Hamilton’s Brief Psychiatric Rating Scale (BPRS) and other standard psychological questionnaires. The findings demonstrated that CA significantly
  alleviated anxiety-related symptoms (p<0.01), reduced stress levels, and correlated depression (p<0.01). Moreover, CA improved willingness for adjustment and cognition (p<0.01). These results suggest that Centella asiatica could be a promising therapeutic option for GAD, exhibiting potential as an anxiolytic agent in the future.
• This double-blind, placebo-controlled study aimed to assess the anxiolytic effects of Gotu Kola (Centella asiatica) in
  healthy subjects. Gotu Kola, a plant used in Ayurvedic and traditional Chinese medicine for centuries to alleviate depression and anxiety symptoms, was investigated for its potential to modulate cholecystokinin (CCK) receptors, which are implicated in anxiety pathophysiology. Subjects were randomly assigned to receive a single oral dose of either Gotu Kola or placebo. Results showed that Gotu Kola significantly reduced the amplitude of the acoustic startle response (ASR) at 30 and 60 minutes post-treatment compared to placebo. However, Gotu Kola had no notable effects on self-rated mood, heart rate, or blood pressure. These initial findings suggest that Gotu Kola may possess anxiolytic properties in humans, as demonstrated by ASR attenuation, warranting further investigation into its therapeutic potential for anxiety disorders.
  

Phlebotonics: In this study, the effects of phlebotonics on reducing time-to-stop bleeding and anal irritation were evaluated in 130 patients with hemorrhoidal disease (HD), bleeding and pain after hemorrhoidectomy, and hemorrhoidal thrombosis over a short period. Patients were divided into three groups: one receiving routine treatment (control Group C), another treated with flavonoids (Group A), and the third treated with Centella (Group B). Time-to-stop bleeding was assessed at baseline and follow-up visits, while healing was estimated using the Kaplan-Meier method. The HD median time-to-stop bleeding was 2 weeks for Groups A and B, and 3 weeks for Group C. Visual Analogue Scale (VAS) scores showed significant differences in anal irritation between Group A vs C and Group B vs C. Operated hemorrhoids also showed improved time-to-stop bleeding in Groups A and B compared to Group C. Histopathology revealed an association between flavonoids and fibrosis of piles. Overall, phlebotonics, particularly flavonoids, demonstrated significant beneficial effects in treating HD and post-surgery hemorrhoids.

Overcome Stress & Anxiety:

• This study examined whether kava or valerian could mitigate the effects of psychological stress in healthy volunteers. Fifty-four participants performed a standardized mental stress task twice, one week apart, with blood pressure (BP), heart rate (HR), and subjective pressure ratings measured at rest and during the task. After the first session, participants took kava (n = 18), valerian (n = 18), or nothing (control, n = 18) for seven days. At the second session, both the kava and valerian groups showed a significant decrease in systolic BP responsivity, though diastolic BP did not significantly change. HR reactivity decreased in the valerian group but not in the kava group. Both kava and valerian groups reported less subjective pressure during the task at the second session, while the control group showed no significant changes. Behavioral performance on the task remained unchanged across all groups. These findings suggest that kava and valerian may help reduce physiological reactivity to stress.
  

• A 4-week double-blind, randomized, placebo-controlled clinical trial with 64 volunteers suffering from psychological stress investigated the effects of valerian root extract (VRE) on functional brain connectivity using EEG. Participants received 100 mg of VRE or a placebo three times daily. Both groups showed significant improvements in anxiety and stress-related symptoms, with no significant differences between the groups in clinical outcomes. However, the VRE group exhibited significantly greater increases in frontal brain region alpha coherence and decreases in theta coherence, which were correlated with reduced anxiety. These results suggest that VRE alters functional brain connectivity related to anxiety. Further EEG studies are needed to confirm these neurophysiological effects.

• Depression: A retrospective, 12-month, open-label, observational, controlled trial was conducted by Francesco Di Pierro of the Department of Scientific Research and Development, Velleja Research, Italy to study the antidepressant clinical activity of a Hypericum Perforatum. The study administered that hypericum extract gave better clinical outcomes in volunteers with depression without determining an increased risk of toxicity or reduced tolerability.

• Depression and menopausal symptoms: Randomized controlled study was conducted on 80 postmenopausal women aged 45-60 in Izeh, Iran by Alieh Eatemadnia of Midwifery Department, Menopause & Andropause Research Centre. Two groups received 270-330 μg of Hypericum perforatum(n = 40) or placebo (n = 40) tablets three times a day for two months. Seventy women
  completed the study and the results show that the treatment with Hypericum perforatum is an efficient way of reducing hot flashes, menopausal symptoms, and depression in postmenopausal women.

• Depression and tiredness: A randomized, placebo-controlled, double-blind study was conducted by W D Hübner , S Lande, H Podzuweit from Lichtwer Pharma GmbH, Berlin, Germany. The study was done on 39 patients with depression with somatic symptoms who were treated with Hypericum perforatum extract LI 160. The volunteers were administered with hypericum extract 300 mg dose thrice a day for 4 weeks. Seventy percent of the patients treated with LI 160 were free of symptoms after 4 weeks. Typical symptoms of depression such as lack of activity, tiredness, fatigue, and disturbed sleep, were especially responsive. In no case were any undesirable side effects observed.

• Fatigue: A randomized, double-blind, parallel-group comparison was done among 240 subjects with mild-moderate depression was done by E Schrader from Praxis Klinische Arzneimittelforschung, Pohlheim, Germany. The patients were treated with hypericum and fluoxetine. After 6 weeks' treatment, it was concluded that hypericum and fluoxetine are equipotent with respect to all main parameters used to investigate antidepressants in this population, although hypericum may be superior in improving the responder rate.

• Sleep Inducing: A study was conducted by A.L. Sharpley, C.L. McGavin, R. Whale P.J. Cowen of the University Department of Psychiatry, Warneford Hospital, UK using healthy volunteers having no history of psychiatric or sleep disorders. They were administered with two doses (0.9 mg and 1.8 mg) of Hypericum perforatum (St John's wort) on the sleep polysomnogram using a placebo-controlled, cross-over design. Both doses of hypericum significantly increased the latency to rapid eye movement (REM) sleep without producing any other effect on sleep architecture.
  
  
  
  

Overall benefit of Passionflower: (Anxiety and Sleep) – Aleksa Ristic an MS from the University of Belgrade quoted all the medicinal benefits of Passion Flower in his journal. Passion Flower is rich in Flavonoids such as vitexin, isovitexin, apigenin, chrysin, orientin, essential oil, Phenolic, and fatty acids. The unique blend of these components in the passion flower, makes it a good component for brain health, heart health, metabolism, and inflammation. In a larger clinical trial (182 patients), an herbal mixture with passion flower relieved anxiety without any significant side effects. In a clinical trial, 91 patients were administered with passion flower extract and the result was a boost in sleep quality and duration.

Relieves insomnia: In the Journal Medicinal Plant in Viet Nam by World Health Organisation, it is mentioned that the whole plant is considered to have sedative properties and is used in the treatment of neurasthenia, insomnia, nightmares, and anxiety. It is also indicated that Passiflora is capable of treating hypertension.

Vitexin as neuroprotective: A brief review was conducted on the neuroprotective properties of Vitexin, the primary bioactive present in Passiflora. After reviewing the effect of vitexin on different neurological disorders. It was concluded that Vitexin contributes to the reduction of neural cell death observed in neurodegenerative diseases and contributed to improving the disabling symptoms observed in Alzheimer’s and Parkinson’s patients. Vitexin proved to be safe and increased cell viability, and improved cognitive and locomotor activities in vivo models.

Metabolism of cortisol: In a post-hoc analysis of a randomized trial, forty-nine overweight men and women aged 45 to 70 years were allocated to receive either a magnesium supplement (350 mg/day) or a placebo for 24 weeks. Urinary cortisol, cortisone, and their metabolites were measured in 24-hour urine samples, and enzymatic activities were estimated. Results showed that after 24 weeks, urinary cortisol excretion decreased in the magnesium group compared to the placebo group (-32 nmol/24-h, 95% CI: -59; -5 nmol/24-h, p = .021). Ratios of certain metabolites were also decreased following magnesium supplementation, indicating an increased activity of 11β-HSD type 2. However, no effects were observed on A-ring reductase activity. These findings suggest a beneficial effect of magnesium supplementation in reducing 24-hour urinary cortisol excretion and potentially lowering cardiovascular disease risk through altered enzyme activity.

Reducing stress: In this randomized, controlled, double-blind trial involving patients with fibromyalgia, the efficacy of once-daily oral magnesium supplementation (100 mg of Chronomag®, magnesium chloride technology formula) was compared to placebo over a period of one month. The primary endpoint was the level of stress measured on the DASS-42 scale, while secondary endpoints included pain, sleep, quality of life, fatigue, catastrophism, social vulnerability, and magnesium blood concentrations. Results indicated that while the DASS-42 scores decreased in both the magnesium and placebo groups after one month, the reduction was not statistically significant (21.8 ± 9.6 vs. 21.6 ± 10.8, respectively, p = 0.930). However, magnesium supplementation notably reduced stress levels in the mild/moderate stress subgroup (DASS-42 stress score: 22.1 ± 2.8 to 12.3 ± 7.0 in magnesium vs. 21.9 ± 11.9 to 22.9 ± 11.9 in placebo, p = 0.003) and significantly diminished pain severity (p = 0.029). Other parameters such as sleep, quality of life, fatigue, catastrophism, and social vulnerability did not significantly differ between the two groups. These findings suggest that daily magnesium supplementation may be beneficial in alleviating stress and reducing pain experienced by fibromyalgia patients, warranting further investigation through larger clinical trials.